{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 462093698
| IUPAC_name = (6''R'',7''S'')-7-<nowiki>[[</nowiki>(2''S'')-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
| image = Loracarbef.png
<!--Clinical data-->
| tradename = Lorabid
| Drugs.com = {{drugs.com|monograph|loracarbef}}
| MedlinePlus = a601206
| pregnancy_category =  
| legal_status =  
| routes_of_administration =  
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound = 25%
| metabolism =  
| elimination_half-life =  
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 76470-66-1
| ATC_prefix = J01
| ATC_suffix = DC08
| PubChem = 5284584
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00447
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4447634
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = W72I5ZT78Z
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08143
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1013
<!--Chemical data-->
| C=16 | H=16 | Cl=1 | N=3 | O=4
| molecular_weight = 349.769 g/mol
| smiles = Cl\C3=C(/C(=O)O)N2C(=O)[C@@H](NC(=O)[C@@H](c1ccccc1)N)[C@H]2CC3.O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C16H16ClN3O4.H2O/c17-9-6-7-10-12(15(22)20(10)13(9)16(23)24)19-14(21)11(18)8-4-2-1-3-5-8;/h1-5,10-12H,6-7,18H2,(H,19,21)(H,23,24);1H2/t10-,11-,12+;/m1./s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = GPYKKBAAPVOCIW-HSASPSRMSA-N
}}

'''Loracarbef''' is an [[antibiotic]].<ref name="pmid8150976">{{cite journal |author=Biedenbach DJ, Jones RN |title=Predictive accuracy of disk diffusion test for Proteus vulgaris and Providencia species against five newer orally administered cephalosporins, cefdinir, cefetamet, cefprozil, cefuroxime, and loracarbef |journal=J. Clin. Microbiol. |volume=32 |issue=2 |pages=559â€“62 |date=February 1994 |pmid=8150976 |pmc=263078 |doi= |url=http://jcm.asm.org/cgi/pmidlookup?view=long&pmid=8150976}}</ref> It is a [[carbacephem]], but it is sometimes grouped together with the second-generation [[cephalosporin]] antibiotics. Loracarbef is a synthetic "carba" [[structural analog|analog]] of [[cefaclor]], and is more stable chemically. 

==History==
Loracarbef received FDA approval in 1991 and it was marketed under the trade name '''Lorabid'''.  Its use was discontinued in 2006.{{fact|date=January 2011}} 

==Side effects==
Diarrhea is the most common adverse effect with loracarbef. Side effects are more frequently seen with children under the age of twelve. 

==References==
{{reflist}}

==External links==
*[http://www.rxlist.com/cgi/generic/loracarb.htm RxList.com - Loracarbef]

{{antibiotic-stub}}
{{Cell wall disruptive antibiotics}}
[[Category:Cephalosporin antibiotics]]
[[Category:Organochlorides]]